OliX Pharmaceuticals, Inc (KOSDAQ:226950)

South Korea flag South Korea · Delayed Price · Currency is KRW
122,400
-9,700 (-7.34%)
At close: Feb 6, 2026
549.34%
Market Cap2.47T +752.7%
Revenue (ttm)10.18B -36.9%
Net Income-43.30B
EPS-2,280.15
Shares Out20.19M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume476,537
Average Volume513,745
Open120,800
Previous Close132,100
Day's Range118,000 - 126,000
52-Week Range16,500 - 161,000
Beta0.55
RSI41.00
Earnings DateMar 20, 2026

About OliX Pharmaceuticals

OliX Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company’s products pipeline includes OLX101A for skin scar; OLX104C for androgenic alopecia; OLX301A for age-related macular degeneration; OLX702A for metabolic dysfunction-associated steatohepatitis; OLX703A for hepatitis; and OLX301D for subretinal fibrosis. The company has a license and collaboration agreement with Hansoh Pharmaceuticals; development collaboration ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 226950
Full Company Profile

Financial Performance

In 2024, OliX Pharmaceuticals's revenue was 5.68 billion, a decrease of -66.73% compared to the previous year's 17.06 billion. Losses were -40.66 billion, 112.9% more than in 2023.

Financial Statements